相关实验视频
Updated: Jul 21, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
255
在阿尔茨海默氏症患者中重新利用提波隆
1Department of Biological Sciences, University of Limerick, V94 T9PX Limerick, Ireland.
Biomolecules
|July 29, 2023
概括
提博在通过保护线粒体和潜在地减少粉样蛋白负担来对抗阿尔茨海默病 (AD) 方面表现有前途. 这种荷尔蒙疗法可能为缓解AD的分子途径提供了一种新的治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 线粒体生物学 线粒体生物学
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β和积,导致认知能力下降.
- 绝经后妇女面临更高的AD风险,可能与雌激素降低和雌激素受体β (ERβ) 活性降低有关.
- 雌激素的下降会影响线粒体功能,影响能量代谢,增加氧化应激.
研究的目的:
- 审查最近在阿尔茨海默病治疗tibolone的治疗潜力的进展.
- 在AD的背景下,专注于tibolone的线粒体保护作用.
- 突出提博隆作为AD的潜在治疗替代品.
主要方法:
- 目前关于tibolone,阿尔茨海默病和线粒体功能的文献的综述.
- 分析tibolone的作用机制,包括类固醇受体调解和神经球蛋白.
- 检查tibolone对粉样蛋白负担和线粒体完整性的影响.
主要成果:
- 蒂博隆可以减少大脑中的粉样蛋白负担.
- 蒂博隆对线粒体的完整性和动态具有保护作用.
- 蒂博隆的益处部分通过类固醇受体进行介导,可能涉及神经球蛋白.
结论:
- 提博隆表现出与阿尔茨海默病相关的显著线粒体保护作用.
- 蒂博隆减轻AD分子途径的能力需要进一步调查.
- 蒂博隆代表了管理阿尔茨海默病的有希望的治疗候选人.
相关概念视频
Alzheimer's Disease: Treatment
218
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
218
Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Parkinson's Disease: Treatment
299
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
299
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K

